Anjay Rastogi
Overview
Explore the profile of Anjay Rastogi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
2156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rastogi A, Weir M
J Diabetes Complications
. 2023 Jun;
37(8):108515.
PMID: 37356235
In patients with chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM), slowing kidney disease progression is an important therapeutic goal. Many patients with T2DM and CKD also...
12.
Rastogi A, Januzzi Jr J
J Clin Med
. 2023 Apr;
12(8).
PMID: 37109162
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to improve cardiovascular and renal outcomes in patients with established cardiovascular disease, chronic kidney disease (CKD), and heart failure (HF) with reduced or...
13.
Rastogi A, Fishbane S, Lerma E
Expert Rev Clin Pharmacol
. 2023 Apr;
16(5):387-400.
PMID: 37010031
Introduction: Chronic kidney disease-associated pruritus (CKD-aP) is often experienced by patients with CKD receiving dialysis. Approximately 40% of hemodialysis patients are 'moderately' to 'extremely bothered' by itching, associated with reduced...
14.
Kanda E, Rastogi A, Murohara T, Lesen E, Agiro A, Arnold M, et al.
BMC Nephrol
. 2023 Jan;
24(1):18.
PMID: 36658531
Background: Hyperkalemia (HK) is a barrier to optimization of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in heart failure (HF) and chronic kidney disease (CKD). We investigated cardiorenal risk associated with changes...
15.
Coyne D, Singh A, Lopes R, Bailey C, DiMino T, Huang C, et al.
Clin J Am Soc Nephrol
. 2022 Aug;
17(9):1325-1336.
PMID: 35918106
Background And Objectives: Daprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being investigated for the treatment of anemia of CKD. In this noninferiority trial, we compared daprodustat administered three...
16.
Spinowitz B, Fishbane S, Fukagawa M, Ford M, Guzman N, Rastogi A
Int J Nephrol
. 2022 May;
2022:6304571.
PMID: 35531468
Background: Evidence of longitudinal serum potassium (sK) concentrations in hyperkalemic hemodialysis patients is sparse. Objective: These post hoc analyses of the placebo arm of the phase 3b DIALIZE study (NCT03303521)...
17.
Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, et al.
Kidney Int Rep
. 2022 May;
7(4):908-912.
PMID: 35497779
No abstract available.
18.
Fishbane S, Pollock C, El-Shahawy M, Escudero E, Rastogi A, Pham Van B, et al.
J Am Soc Nephrol
. 2022 Apr;
33(4):850-866.
PMID: 35361724
Background: Concerns regarding cardiovascular safety with current treatments for anemia in patients with dialysis-dependent (DD)-CKD have encouraged the development of alternatives. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates...
19.
Nobakht N, Hanna R, Kamgar M, Sinclair J, Simon L, Emami S, et al.
Clin Case Rep
. 2022 Mar;
10(3):e05432.
PMID: 35340649
A 70-year-old female patient developed acute interstitial nephritis (AIN) after treatment with non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPI), and Bromhexine. Renal biopsy confirmed the diagnosis, and the patient...
20.
Dolui S, Detre J, Gaussoin S, Herrick J, Wang D, Kurella Tamura M, et al.
JAMA Neurol
. 2022 Mar;
79(4):380-389.
PMID: 35254390
Importance: Antihypertensive treatments benefit cerebrovascular health and cognitive function in patients with hypertension, but it is uncertain whether an intensive blood pressure target leads to potentially harmful cerebral hypoperfusion. Objective:...